Larimar Therapeutics Stock Performance
| LRMR Stock | USD 2.93 0.02 0.68% |
The company secures a Beta (Market Risk) of 1.89, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Larimar Therapeutics will likely underperform. At this point, Larimar Therapeutics has a negative expected return of -1.15%. Please make sure to verify Larimar Therapeutics' treynor ratio, accumulation distribution, as well as the relationship between the Accumulation Distribution and period momentum indicator , to decide if Larimar Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Larimar Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Even with weak performance in the last few months, the Stock's primary indicators remain relatively invariable which may send shares a bit higher in March 2025. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors. ...more
Actual Historical Performance (%)
One Day Return (2.64) | Five Day Return (11.41) | Year To Date Return (26.43) | Ten Year Return (99.37) | All Time Return (98.76) |
Last Split Factor 1:12 | Dividend Date 2020-05-29 | Last Split Date 2020-05-29 |
1 | Acquisition by Everett Wendy of 27000 shares of Larimar Therapeutics at 1.25 subject to Rule 16b-3 | 11/26/2024 |
2 | Acquisition by Truitt Joseph of 8300 shares of Larimar Therapeutics at 5.09 subject to Rule 16b-3 | 12/04/2024 |
3 | Larimar Therapeutics Announces Positive Initial Data from Ongoing Long-term Open Label ... | 12/16/2024 |
4 | Whats Going On With Larimar Therapeutics Stock On Tuesday | 12/17/2024 |
5 | William Blair Has Pessimistic Outlook of LRMR Q1 Earnings | 12/19/2024 |
6 | Acquisition by Celano Michael of 20000 shares of Larimar Therapeutics at 2.92 subject to Rule 16b-3 | 12/20/2024 |
7 | Bullish Larimar Therapeutics Insiders Loaded Up On US522.0k Of Stock | 01/06/2025 |
8 | SLDB Stock Up as FDA Clears IND for SGT-212 in Friedreichs Ataxia | 01/08/2025 |
9 | Acquisition by Shankar Gopi of 22500 shares of Larimar Therapeutics subject to Rule 16b-3 | 01/17/2025 |
10 | Acquisition by Celano Michael of 34185 shares of Larimar Therapeutics subject to Rule 16b-3 | 01/22/2025 |
11 | Larimar Therapeutics Announces Dosing of Adolescents in Nomlabofusp Pediatric Pharmacokinetic Run-In Study for Patients with Friedreichs Ataxia | 01/23/2025 |
12 | Disposition of tradable shares by Chondrial Therapeutics Holdings, Llc of Larimar Therapeutics subject to Rule 16b-3 | 01/29/2025 |
13 | BlackRock, Inc. Increases Stake in Larimar Therapeutics Inc - GuruFocus.com | 02/05/2025 |
14 | Acquisition by Flynn James E of 1430206 shares of Larimar Therapeutics at 8.74 subject to Rule 16b-3 | 02/20/2025 |
15 | Acquisition by Barrett Peter of 8300 shares of Larimar Therapeutics at 10.34 subject to Rule 16b-3 | 02/21/2025 |
| Begin Period Cash Flow | 26.8 M | |
| Free Cash Flow | -33.6 M |
Larimar |
Larimar Therapeutics Relative Risk vs. Return Landscape
If you would invest 633.00 in Larimar Therapeutics on November 28, 2024 and sell it today you would lose (335.00) from holding Larimar Therapeutics or give up 52.92% of portfolio value over 90 days. Larimar Therapeutics is currently does not generate positive expected returns and assumes 4.7339% risk (volatility on return distribution) over the 90 days horizon. In different words, 42% of stocks are less volatile than Larimar, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Larimar Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Larimar Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Larimar Therapeutics, and traders can use it to determine the average amount a Larimar Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.2434
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | LRMR |
Estimated Market Risk
| 4.73 actual daily | 42 58% of assets are more volatile |
Expected Return
| -1.15 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.24 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Larimar Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Larimar Therapeutics by adding Larimar Therapeutics to a well-diversified portfolio.
Larimar Therapeutics Fundamentals Growth
Larimar Stock prices reflect investors' perceptions of the future prospects and financial health of Larimar Therapeutics, and Larimar Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Larimar Stock performance.
| Return On Equity | -0.44 | ||||
| Return On Asset | -0.29 | ||||
| Current Valuation | (5.01 M) | ||||
| Shares Outstanding | 63.81 M | ||||
| Price To Book | 0.97 X | ||||
| EBITDA | (41.45 M) | ||||
| Net Income | (36.95 M) | ||||
| Cash And Equivalents | 54.92 M | ||||
| Cash Per Share | 3.10 X | ||||
| Total Debt | 5.55 M | ||||
| Debt To Equity | 0.11 % | ||||
| Current Ratio | 7.35 X | ||||
| Book Value Per Share | 3.11 X | ||||
| Cash Flow From Operations | (33.46 M) | ||||
| Earnings Per Share | (1.15) X | ||||
| Market Capitalization | 188.23 M | ||||
| Total Asset | 95.94 M | ||||
| Retained Earnings | (188.55 M) | ||||
| Working Capital | 80.67 M | ||||
About Larimar Therapeutics Performance
Assessing Larimar Therapeutics' fundamental ratios provides investors with valuable insights into Larimar Therapeutics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Larimar Therapeutics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | (267.82) | (254.43) | |
| Return On Tangible Assets | (0.44) | (0.47) | |
| Return On Capital Employed | (0.43) | (0.41) | |
| Return On Assets | (0.44) | (0.47) | |
| Return On Equity | (0.41) | (0.39) |
Things to note about Larimar Therapeutics performance evaluation
Checking the ongoing alerts about Larimar Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Larimar Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Larimar Therapeutics generated a negative expected return over the last 90 days | |
| Larimar Therapeutics has high historical volatility and very poor performance | |
| Net Loss for the year was (36.95 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Larimar Therapeutics currently holds about 54.92 M in cash with (33.46 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.1, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Larimar Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Over 98.0% of the company shares are owned by institutional investors | |
| Latest headline from MacroaxisInsider: Acquisition by Barrett Peter of 8300 shares of Larimar Therapeutics at 10.34 subject to Rule 16b-3 |
- Analyzing Larimar Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Larimar Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Larimar Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Larimar Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Larimar Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Larimar Therapeutics' stock. These opinions can provide insight into Larimar Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Larimar Stock Analysis
When running Larimar Therapeutics' price analysis, check to measure Larimar Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Larimar Therapeutics is operating at the current time. Most of Larimar Therapeutics' value examination focuses on studying past and present price action to predict the probability of Larimar Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Larimar Therapeutics' price. Additionally, you may evaluate how the addition of Larimar Therapeutics to your portfolios can decrease your overall portfolio volatility.